AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Effects: Flunisolide works by reducing inflammation in the airways, making it easier for individuals with respiratory conditions to breathe. It acts by inhibiting the production of inflammatory mediators and suppressing the immune response in the lungs.
Management of Asthma: Flunisolide is commonly prescribed for the long-term management of asthma, a chronic respiratory condition characterized by inflammation and narrowing of the airways. It helps to control asthma symptoms such as wheezing, shortness of breath, coughing, and chest tightness.
Treatment of Allergic Rhinitis: Flunisolide nasal spray is also used for the treatment of allergic rhinitis (hay fever), which causes symptoms such as nasal congestion, sneezing, runny nose, and itching. By reducing inflammation in the nasal passages, flunisolide helps alleviate these symptoms.
Prevention of Nasal Polyps: Flunisolide nasal spray may be prescribed to prevent the recurrence of nasal polyps, which are noncancerous growths in the lining of the nasal passages. It helps reduce inflammation and shrink existing polyps, as well as prevent the formation of new ones.
Chronic Obstructive Pulmonary Disease (COPD): Flunisolide may be used as part of the treatment regimen for COPD, a progressive lung disease that includes chronic bronchitis and emphysema. It helps reduce inflammation in the airways and improve breathing in individuals with COPD.
Dosage and Administration: Flunisolide is available in various formulations, including nasal sprays and inhalers. The dosage and frequency of administration depend on the specific condition being treated, the severity of symptoms, and the individual's response to the medication. It is usually administered as directed by a healthcare professional.
Side Effects: While generally well-tolerated, flunisolide may cause side effects in some individuals. Common side effects may include nasal irritation, dryness or stinging sensation in the nose, sneezing, headache, and nosebleeds. These side effects are usually mild and temporary.
Systemic Effects: When used in high doses or for prolonged periods, corticosteroids like flunisolide may be absorbed into the bloodstream, potentially leading to systemic side effects such as adrenal suppression, bone thinning (osteoporosis), cataracts, and increased susceptibility to infections.
Precautions: Flunisolide should be used with caution in individuals with a history of nasal septum ulcers, nasal surgery, or recent nasal trauma. It is not recommended for use in people with active tuberculosis or untreated fungal, bacterial, or viral infections of the respiratory tract.
Drug Interactions: Flunisolide may interact with other medications, including other corticosteroids, antifungal drugs, and certain antibiotics. It is essential to inform healthcare providers about all medications, supplements, and herbal products being taken to avoid potential interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.1 | 0.4 | -3 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
| Allergies | 0.2 | 0.1 | 1 |
| Allergy to milk products | 0.1 | 0.1 | |
| Alzheimer's disease | 0.3 | 0.9 | -2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0 | 0 |
| Ankylosing spondylitis | 0.1 | 0.2 | -1 |
| Anorexia Nervosa | 0.3 | -0.3 | |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 0.2 | -0.2 | |
| Atherosclerosis | 0 | 0.4 | 0 |
| Atrial fibrillation | 0.7 | 0.1 | 6 |
| Autism | 0.7 | 1.2 | -0.71 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| Bipolar Disorder | 0.1 | 0.5 | -4 |
| Brain Trauma | 0.2 | -0.2 | |
| Carcinoma | 0.2 | 0.1 | 1 |
| Celiac Disease | 0.2 | 0.2 | 0 |
| Cerebral Palsy | 0.1 | 0.2 | -1 |
| Chronic Fatigue Syndrome | 0.8 | 1.3 | -0.63 |
| Chronic Kidney Disease | 0.1 | 0.6 | -5 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.6 | -0.5 |
| Chronic Urticaria (Hives) | 0.1 | 0.2 | -1 |
| Coagulation / Micro clot triggering bacteria | 0.1 | 0.3 | -2 |
| Colorectal Cancer | 0.7 | 0.7 | |
| Constipation | 0.2 | 0.1 | 1 |
| Coronary artery disease | 0 | 0.4 | 0 |
| COVID-19 | 0.8 | 2 | -1.5 |
| Crohn's Disease | 0.8 | 1.1 | -0.38 |
| cystic fibrosis | 0.2 | -0.2 | |
| deep vein thrombosis | 0.3 | -0.3 | |
| Depression | 1.9 | 2.4 | -0.26 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.6 | -0.6 | |
| Endometriosis | 0.6 | 0.1 | 5 |
| Epilepsy | 0.4 | 0.1 | 3 |
| Fibromyalgia | 0.7 | 0.8 | -0.14 |
| Functional constipation / chronic idiopathic constipation | 0.7 | 0.8 | -0.14 |
| gallstone disease (gsd) | 0 | 0.1 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.1 | 1 |
| Generalized anxiety disorder | 0.5 | -0.5 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.4 | -0.4 | |
| Graves' disease | 0.1 | 0.1 | 0 |
| Halitosis | 0.1 | 0.1 | 0 |
| Hashimoto's thyroiditis | 0.2 | 0.1 | 1 |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.3 | 0.3 | |
| hyperglycemia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.2 | 0.9 | -3.5 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.2 | -0.2 | |
| Inflammatory Bowel Disease | 1.2 | 1.2 | 0 |
| Insomnia | 0.2 | 0.3 | -0.5 |
| Intelligence | 0.4 | 0.4 | |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 0.2 | 0.3 | -0.5 |
| Liver Cirrhosis | 0.7 | 0.7 | 0 |
| Long COVID | 1.6 | 0.9 | 0.78 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0 | 0 | |
| ME/CFS with IBS | 0.1 | 0.8 | -7 |
| ME/CFS without IBS | 0.2 | 0.1 | 1 |
| Metabolic Syndrome | 0.9 | 0.9 | 0 |
| Mood Disorders | 2.3 | 2.4 | -0.04 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 0.4 | 0.8 | -1 |
| Multiple system atrophy (MSA) | 0 | 0 | |
| Neuropathy (all types) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.6 | -5 |
| Obesity | 0.7 | 1.6 | -1.29 |
| obsessive-compulsive disorder | 0.6 | 0.5 | 0.2 |
| Osteoarthritis | 0.8 | 0 | 0 |
| Osteoporosis | 0.1 | 0.1 | 0 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.5 | 1.2 | -1.4 |
| Polycystic ovary syndrome | 0.1 | 0.2 | -1 |
| Postural orthostatic tachycardia syndrome | 0.4 | -0.4 | |
| Psoriasis | 0.3 | 0.6 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.8 | 0.8 | 0 |
| Rosacea | 0 | 0.1 | 0 |
| Schizophrenia | 0.6 | 0.5 | 0.2 |
| scoliosis | 0.4 | 0.2 | 1 |
| Sjögren syndrome | 0.1 | 0.1 | 0 |
| Sleep Apnea | 0.4 | 0.6 | -0.5 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 0.2 | 0.6 | -2 |
| Systemic Lupus Erythematosus | 0.8 | 0.2 | 3 |
| Tic Disorder | 0 | 0 | |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.7 | 0.3 | 1.33 |
| Type 2 Diabetes | 0.9 | 0.9 | 0 |
| Ulcerative colitis | 0.7 | 0.6 | 0.17 |
| Unhealthy Ageing | 0.8 | 0.5 | 0.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.